Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy

1. 14-gene molecular assay shows potential in identifying early-stage nonsquamous NSCLC patients for adjuvant chemotherapy. 2. Patients receiving adjuvant chemotherapy had significantly lower risk of cancer recurrence. 3. Interim results suggest a shift towards more precise, biomarker-driven therapy decisions. 4. Promising implications for targeted therapy and immunotherapy in earlier stages of NSCLC. 5. Study funded by Razor Genomics.